Overview

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Assess if aliskiren is capable of enhancing vascular stiffness and endothelial function and compare theses effects and renin activity and concentration to those obtained with a calcium channel blocker, amlodipine, in patients with diabetes mellitus type 2 and blood pressure not controlled by 100 mg per day of losartan.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitario Pedro Ernesto
Collaborator:
Novartis
Treatments:
Amlodipine
Losartan